Silo Pharma enters $1.51-per-share warrant deal with Norsight for software and IP assets
Silo Pharma agreed on October 1, 2026 to buy software, technology and related intellectual property from Norsight Consulting Inc. In payment, it issued Norsight a warrant to buy up to 300,000 shares of common stock at $1.51 per share, a sale made without registration. The filing describes no cash consideration, so the deal adds potential dilution for shareholders while expanding the company's asset base.
Key points
- Asset purchase agreement dated October 1, 2026 with Norsight Consulting Inc., an Arkansas corporation
- Warrant covers up to 300,000 shares at an exercise price of $1.51 per share, exercisable from April 1, 2027 and expiring September 30, 2031
- Seller may not hold more than 4.99% of outstanding common stock after exercise, and may not exceed 9.99% without at least 61 days' notice
- Shares received by the seller are locked up for up to 12 months, or until a change in control or the company's written consent
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.